Keywords: Langerhans cell histiocytosis; BRAF; MAPK signaling; Dendritic cell; Myeloid differentiation;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Langerhans cell histiocytosis; Neurodegeneration; Oncogenes; BRAF; Chemotherapy;
Keywords: conventional melanoma; melanoma; metastasis; prognosis; sentinel lymph node; sentinel lymph node biopsy; Spitzoid malignant melanoma; survival; BRAF; v-raf murine sarcoma viral oncogene homolog B; CMM; conventional malignant melanoma; HRAS; Harvey rat sar
Keywords: Thyroid cancer; Urokinase plasminogen activating system; Estrogen receptor; miRNA; BRAF; TNM; Prognosis
Keywords: Melanoma; targeted; therapy; molecular; BRAF; TILs
Keywords: BRAF; female genital melanomas; female genital nevi; KIT; NRAS; oncogenic mutations; BRAF; v-raf murine sarcoma viral oncogene homolog B; KIT; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog, CD117; NRAS; neuroblastoma RAS viral (v-ras) onco
Keywords: KRAS; Lung; Young; Molecular; EGFR; ALK; BRAF; Non-small cell lung carcinoma; Fine needle aspiration
Keywords: EGFR; epidermal growth factor receptor; NSCLC; non-small cell lung cancer; TKI; tyrosine kinase inhibitor; WT; wild type; KRAS; Kirsten RNA associated rat sarcoma 2 virus gene; PTEN; phosphatase and tensin homolog; HGF; hepatocyte growth factor; IGF1R; in
Keywords: ATC; anaplastic thyroid carcinoma; DTC; differentiated thyroid carcinomas; FTC; follicular thyroid carcinoma; FTS; farnesylthiosalicylic acid; FVPTC; follicular variant papillary thyroid carcinoma; HDAC; histone deacetylase; IDH; isocitrate dehydrogenase;
Keywords: Melanoma; BRAF; Mitogen-activated extracellular kinase; Immunotherapy; Combination therapy; Targeted therapy;
Keywords: Thyroid cancer; Prognosis; Molecular genetics; BRAF; RAS; RET/PTC; PAX8-PPAR; Targeted therapy;
Keywords: Single nucleotide polymorphism; BRAF; KIAA1549; FAM131B; TP53; MYB; QKI; medulloblastoma; glioma; ependymoma; astrocytoma
Keywords: Thyroid; Neoplasm; Molecular pathology; BRAF; RAS; RET/PTC; PAX8/PPARγ; Veracyte; Afirma;
Keywords: Pediatric; Low-grade glioma; Genetics; BRAF;
Keywords: Melanoma; Targeted therapy; MAPK signaling; BRAF; MEK; NRAS;
Keywords: BRAF; NRAS; Immunotherapy; Targeted therapy; MITF;
Keywords: Thyroid cancer; Differentiated thyroid cancer; Molecular biology; BRAF; RET/PTC; PAX8/PPARγ
Keywords: Melanoma; Brain metastases; Vemurafenib; Dabrafenib; BRAF; Ipilimumab; Blood brain barrier;
Keywords: BRAF; B-Raf protein; BRD4; bromodomain-containing protein 4; CDK6; cyclin-dependent kinase 6; ERBB1; epidermal growth factor receptor; ERG; ETS-family oncogenic transcription factor; ERK; extracellular signal regulated protein kinase; FOS; FBJ murine oste
Keywords: Serrated polyps; serrated polyposis; appendix; KRAS; BRAF; CIMP
Keywords: BRAF; diagnosis; KIT; melanoma; molecular testing; NRAS; OncoCarta; pathology; somatic mutations; targeted therapy
The dilemma of diagnosing coenzyme Q10 deficiency in muscle
Keywords: Coenzyme Q10 deficiency; Complex II+III; Electron transport chain; OXPHOS; Reference range; CI to CIV; Respiratory chain enzyme complexes I to IV respectively; CS; Citrate synthase; RCD; Respiratory chain deficiency; CRC; Clinically referred controls; PDS
Les thérapies ciblées per os
Keywords: angiogenèse; BCR/ABL; BRAF; EGFR; inhibiteur de kinase; MEK; thérapie ciblée; angiogenesis; BCR/ABL; BRAF; EGFR; kinase inhibitor; MEK; targeted therapy;
Association of the 16q24.3 region gene variants rs1805007 and rs4785763 with heightened risk of melanoma in Latvian population
Keywords: ACD; adrenocortical dysplasia protein homolog gene; AFG3L1P; AFG3-like matrix AAA peptidase subunit 1 of the pseudogene; BAP1; BRCA1 associated protein-1 gene; BRAF; serine/threonine-protein kinase B-Raf; CDK4; cyclin-dependent kinase 4; CDK10; cyclin-dep
Orbital and chorioretinal manifestations of Erdheim-Chester disease treated with vemurafenib
Keywords: Histiocytosis; Vemurafenib; Orbital; Chorioretinal; Xanthomatous; Lipogranulomatous; BRAF;
Melanoma metabolism contributes to the cellular responses to MAPK/ERK pathway inhibitors
Keywords: MAPK; mitogen-activated protein kinase; BRAF; v-raf murine sarcoma viral oncogene homolog B1; MEK; mitogen-activated protein/extracellular signal- regulated kinase kinase; ERK; extracellular signal-regulated kinase; HIF-1α; hypoxia inducible factor 1 alp
BRAF and KRAS mutations in tubular apocrine adenoma and papillary eccrine adenoma of the skin
Keywords: Tubular apocrine adenoma; Papillary eccrine adenoma; RAS; BRAF; Syringocystadenoma papilliferum;
The post-surgical era of GBM: How molecular biology has impacted on our clinical management. A review
Keywords: Glioblastoma; MGMT; IDH1; IDH2; TERT; BRAF; High grade gliomas; Molecular biology;
Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)
Keywords: ALK; anaplastic lymphoma kinase; BRAF; v-Raf murine sarcoma viral oncogene homolog B; cMET; tyrosine-protein kinase Met/hepatocyte growth factor receptor; CT; computer tomography; ECOG; PS Eastern Cooperative Oncology Group performance status; EGFR; epide
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma
Keywords: Antibody-drug conjugate (ADC); HER-3; Melanoma; BRAF; Vemurafenib;
Langerhans cell histiocytosis in children
Keywords: BRAF; Langerhans cell histiocytosis; MAPK; pathway myeloid neoplasia; ECD; Erdheim-Chester disease; LCH; Langerhans cell histiocytosis;
Clinical significance of BRAF non-V600E mutations in colorectal cancer: a retrospective study of two institutions
Keywords: BRAF; Non-V600E; V600E; Next generation sequencing; Comprehensive genomic sequencing; Colorectal cancer;
Langerhans cell histiocytosis in children
Keywords: BRAF; cladribine; clofarabine; cytarabine; diabetes insipidus; Langerhans cell histiocytosis; steroids; vinblastine;
Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies
Keywords: ASCO; American Society of Clinical Oncology; BRAF; B-raf proto-oncogene, serine/threonine kinase; CTLA4; cytotoxic T-lymphocyte associated protein 4; ESMO; European Society for Medical Oncology; FDA; Food and Drug Administration; ICER; incremental cost-ef
The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells
Keywords: AKT; protein kinase B (or PKB); ATC; anaplastic thyroid carcinoma; BRAF; v-Raf murine sarcoma viral oncogene homolog B (or B-RAF); EMT; epithelial-mesenchymal transition; ERK; extracellular signal-regulated kinase (or mitogen-activated protein kinase 1);
The largest CAP-certified Chinese reference laboratory experience with the Bethesda system for reporting thyroid cytopathology: correlation with histologic and BRAF data
Keywords: Thyroid FNA; TBSRTC; Thyroid cancer; China; Thyroid histology; BRAF;
Extracellular vesicles or free circulating DNA: where to search for BRAF and cKIT mutations?
Keywords: Free-circulating DNA; Extracellular vesicles; BRAF; BRAFV600E; cKIT; cKITD816V; Liquid biopsy; Therapy monitoring; Predictive biomarkers;
Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial
Keywords: AJCC; American Joint Committee on Cancer; AP; alkaline phosphatase; BRAF; v-Raf murine sarcoma viral oncogene homolog B; CI; confidence interval; CRC; (colorectal cancer); CT; computed tomography; ECOG; Eastern Cooperative Oncology Group scale of performa
Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
Keywords: Binimetinib (PubChem CID: 10288191); Cobimetinib (PubChem CID: 16222096); Dabrafenib (PubChem CID: 44462760); Encorafenib (PubChem CID: 50922675); Trametinib (PubChem CID: 11707110); Vemurafenib (PubChem CID: 42611257); ATC; adoptively transferred T cells
JNK1 as a signaling node in VDR-BRAF induction of cell death in AML
Keywords: AP-1; Activator protein 1, c-Jun and dimerization partners; AKT; Serine/threonine protein kinase B (PKB); AML; Acute myeloid leukemia; AraC; Cytarabine/Arabinocytosine; ASK1; Apoptosis signal regulating kinase 1; BCL2; B-cell lymphoma 2; BIM; Bcl-2-like p
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors
Keywords: BRAF; lung cancer; PD-1; PD-L1; immune check-point inhibitors;
Piperine potentiates curcumin-mediated repression of mTORC1 signaling in human intestinal epithelial cells: implications for the inhibition of protein synthesis and TNFα signaling
Keywords: Akt; AKT serine/threonine kinase 1; BCA; bicinchoninic acid; BRAF; B-Raf proto-oncogene, serine/threonine kinas; COX-2; cyclooxygenase-2; CUR; curcumin; CYP3A4; cytochrome P450 3A4; DMSO; dimethyl sulfoxide; DTT; dithiothreitol; eEF2; eukaryotic translati
Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors
Keywords: Thyroid nodule; RAS genes; EZH1; BRAF; TERT; Molecular diagnostics;
Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence
Keywords: Colorectal liver metastases; Gene; KRAS; BRAF; TP53; PIK3CA;
Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features
Keywords: BRAF; dermatopathology; gene; histomorphology; immunohistochemistry; melanocytic nevus; melanoma; mutation; SD; standard deviation;
Targeted-gene silencing of BRAF to interrupt BRAF/MEK/ERK pathway synergized photothermal therapeutics for melanoma using a novel FA-GNR-siBRAF nanosystem
Keywords: GNR; gold nanorods; siRNA; small interfering RNA; siBRAF; siRNA specific for BRAF; FA; folic acid; CTAB; cetyltrimethylammonium bromide; MUA; mercaptoundecanoic acid; PEI; polyethylene imine; TEM; transmission electron microscope; NMR; nuclear magnetic re
The association between dermoscopic features and BRAF mutational status in cutaneous melanoma: Significance of the blue-white veil
Keywords: blue-white veil; BRAF; dermatology; dermoscopy; exophytic papillary structures; genetics; melanoma; oncology; pathology; ulceration; streaks;
Non-tumor adjacent tissue of advanced stage from CRC shows activated antioxidant response
Keywords: CRC; colorectal cancer; SIRT3; sirtuin 3; MSI; microsatellite instability; NRAS; neuroblastoma RAS viral oncogene homolog; BRAF; v-raf murine sarcoma viral oncogene homolog B; KRAS; Kirsten rat sarcoma viral oncogene homolog; PI3K; phosphatidylinositide 3
Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer
Keywords: BRAF; Chemotherapy; Epidermal growth factor receptor; RAS; Survival;
Design, synthesis, mechanistic and histopathological studies of small-molecules of novel indole-2-carboxamides and pyrazino[1,2-a]indol-1(2H)-ones as potential anticancer agents effecting the reactive oxygen species production
Keywords: Indole-2-carboxamides; Pyrazino[1,2-a]indole; EGFR; BRAF; Docking; Anti-cancer; Anti-oxidant;